Harnessing proteogenomics in the quest for new drug targets
Editorial Article: Harnessing cutting-edge proteogenomics in the quest for novel drug targets Discover how collaborative research between big pharma and academia is using the latest proteomics platforms to revolutionize drug discovery 10 May 2021 Dr. Anders Mälarstig, Director of Target Sciences at Pfizer Worldwide Research and Development With the advent of high-throughput multiplexed proteomic technology, the days of the standard pre-clinical disease model in drug discovery might be numbered. As the pharmaceutical industry looks towards more human-based discovery of novel drug targets, the...
Source: selectscience.net